PMID- 15459489
OWN - NLM
STAT- MEDLINE
DCOM- 20041026
LR  - 20220227
IS  - 0030-2414 (Print)
IS  - 0030-2414 (Linking)
VI  - 67
IP  - 1
DP  - 2004
TI  - Protein kinase C alpha expression in breast and ovarian cancer.
PG  - 1-10
AB  - In recent years research has focused on the development of specific, targeted 
      drugs to treat cancer. One approach has been to block intracellular signaling 
      proteins, such as protein kinase C alpha (PKC-alpha). To help support the 
      rationale for clinical studies of a PKC-alpha-targeted therapy in breast and 
      ovarian cancers, we reviewed publications studying PKC-alpha expression in these 
      tumors. Since these investigations were mostly performed in cell lines, we 
      supplemented this review with some preliminary findings from studies examining 
      PKC-alpha expression in tumor tissue biopsies obtained from patients with breast 
      and ovarian cancer. Based on the reviewed publications using representative cell 
      lines and our preliminary findings on tumor tissue of patients with breast 
      cancer, we infer that PKC-alpha levels may especially be increased in breast 
      cancer patients with low or negative estrogen receptor (ER) levels. Thus, 
      clinical studies determining efficacy of selective or specific inhibitors of 
      PKC-alpha should include determination of ER status in order to help answer 
      whether blocking PKC-alpha in patients with low or absent ER can result in 
      clinical benefit.
CI  - Copyright 2004 S. Karger AG, Basel
FAU - Lahn, Michael
AU  - Lahn M
AD  - Divison of Oncology Product Development, Lilly Research Laboratories, Eli Lilly, 
      Indianapolis, IN 46285, USA. MichaLahn@aol.com
FAU - Kohler, Gabriele
AU  - Kohler G
FAU - Sundell, Karen
AU  - Sundell K
FAU - Su, Chen
AU  - Su C
FAU - Li, Shuyu
AU  - Li S
FAU - Paterson, Blake M
AU  - Paterson BM
FAU - Bumol, Thomas F
AU  - Bumol TF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Oligonucleotides, Antisense)
RN  - 0 (Phosphorothioate Oligonucleotides)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.11.13 (PRKCA protein, human)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 2.7.11.13 (Protein Kinase C-alpha)
RN  - FMT95051CQ (aprinocarsen)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Breast Neoplasms/*enzymology/epidemiology/genetics
MH  - Drug Resistance, Multiple
MH  - Drug Resistance, Neoplasm
MH  - Enzyme Inhibitors/therapeutic use
MH  - Female
MH  - Gene Expression Regulation, Enzymologic
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Oligonucleotides, Antisense/therapeutic use
MH  - Ovarian Neoplasms/*enzymology/epidemiology/genetics
MH  - Phosphorothioate Oligonucleotides
MH  - Protein Kinase C/antagonists & inhibitors/genetics/*metabolism
MH  - Protein Kinase C-alpha
MH  - Receptors, Estrogen/metabolism
RF  - 72
EDAT- 2004/10/02 05:00
MHDA- 2004/10/27 09:00
CRDT- 2004/10/02 05:00
PHST- 2003/06/13 00:00 [received]
PHST- 2004/01/19 00:00 [accepted]
PHST- 2004/10/02 05:00 [pubmed]
PHST- 2004/10/27 09:00 [medline]
PHST- 2004/10/02 05:00 [entrez]
AID - 80279 [pii]
AID - 10.1159/000080279 [doi]
PST - ppublish
SO  - Oncology. 2004;67(1):1-10. doi: 10.1159/000080279.